Trial Profile

Assessing Long-Term Outcomes of DUPIXENT Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Nasal polyps; Rhinosinusitis
Focus Therapeutic Use
Acronyms AROMA
Sponsors Regeneron Pharmaceuticals

Most Recent Events

16 May 2024 Status changed from recruiting to active, no longer recruiting.
26 Feb 2024 Results ( As of February 7, 2023, n=303)presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
26 Feb 2024 Results (n=303) assessing baseline disease characteristics among patients with chronic rhinosinusitis with nasal polyps and coexisting asthma presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com